Loading
PRCC (Proline-rich protein PRCC) is a gene. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role.
May regulate cell cycle progression through interaction with MAD2L2.
Open Targets scores its association with cancer at 0.54 (direct and indirect evidence; datatypes literature 0.96, genetic association 0.23, somatic mutation 0.80).
In plain words · PRCC (Proline-rich protein PRCC) is a gene. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role.
PRCC (Proline-rich protein PRCC) is a gene. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role.
May regulate cell cycle progression through interaction with MAD2L2. Location: Nucleus (UniProt).
No product in this corpus aims at PRCC yet. Drugs bind the molecule precisely: to switch it off, flag the cell for the immune system, or deliver a payload.
First described 1996. Earliest sequence paper UniProt cites for the protein: Sidhar S.K. et al, Hum. Mol. Genet, 1996, "The t(X;1)(p11.2;q21.2) translocation in papillary renal cell carcinoma fuses a novel gene PRCC to the TFE3 transcription factor gene". Source.
Sources: HGNC HGNC:9343 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q92733 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000143294 (association with cancer (MONDO_0004992) 0.54; (GraphQL API, CC0))
May regulate cell cycle progression through interaction with MAD2L2. Location: Nucleus (UniProt). Locus 1q23.1 (HGNC).
Query for this target: (TITLE:"PRCC" OR ABSTRACT:"PRCC" OR TITLE:"proline rich mitotic checkpoint control factor" OR ABSTRACT:"proline rich mitotic checkpoint control factor" OR TITLE:"Proline-rich protein PRCC" OR ABSTRACT:"Proline-rich protein PRCC" OR TITLE:"RCCP1" OR ABSTRACT:"RCCP1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about PRCC, not a curated reading list.
Shares Savolitinib vs. Sunitinib in MET-driven PRCC., Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC.
Shares Savolitinib vs. Sunitinib in MET-driven PRCC., Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC.